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  About the Irish College of General Practitioners 
 
 
The Irish College General Practitioners (ICGP) is the professional body for general practice in 
Ireland. The College's primary aim is to serve the patient and the general practitioner by 
encouraging and maintaining the highest standards of general medical practice. It is the 
representative organisation on education, training and standards in general practice. 
The College is the recognised body for the accreditation of specialist training in general 
practice in Ireland and is recognised by the Medical Council as the representative academic 
body for the specialty of general practice. 
 
 
There are 3,724 members and associates in the college, comprising over 85% of practising 
GPs in the Republic of Ireland. There are 205 members in Northern Ireland, the United 
Kingdom, Canada and other overseas locations, and 690 GP trainees. 
 
 
ICGP representatives: 
Dr John O’Brien                         ICGP Vice President & Incoming College President 
Dr Mark Murphy                       Chair of Communications & Member of the Board 
 
 
 
   ICGP Opening Statement 
 
The ICGP thanks the Chair and Members of the Joint Committee on Health for the invitation to 
discuss prescription pattern monitoring and the audit of usage and effectiveness trends for 
prescribed medications. 
 
Prescribing is a key professional activity for General Practitioners. It is estimated that a 
prescription is generated in two out of every three consultations. It is GPs who reconcile and 
coordinate patient’s medications as they transition between different healthcare interfaces. It 
is GPs who issue repeat prescriptions for the Irish population. It is GPs who are best placed to 
share decisions with patients on medications, factoring their preferences on the possible 
benefits the possible harms. Monitoring the usage, the effectiveness and trends for prescribed 
medications are essential, for a high quality healthcare system. This submission is composed of 
four sections. 
 
The first section outlines the context to prescribing trends in the Irish healthcare system. The  
prevalence  of  chronic  diseases  and  multimorbidity  is  increasing  in  Irish society, though is 
not reflected in a modern GP contract. Rising prevalence of chronic diseases and an ageing 
population has resulted in a rise in the dispensing and costs of medications in the annual health 
budget. Our submission outlines our expenditure on pharmaceutical products, but in summary 
we spend approximately €2 billion on medications, which is taken from the community budget. 
 
In  contrast  to  the  drug  budget,  Irish  General  Practice  is  extremely  poorly resourced.  We 
spend <4.5% of  our  overall  healthcare  budget  on  General Practice.  At a time when GP-led, 
community-orientated healthcare should have happened, we have seen a massive retraction in 
GP funding. FEMPI cuts are still imposed on General Practice, which limit time for patient care.  
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We work off a 40 year-old out-dated contract. We have severe capacity restraints, with 6.2 GPs 
per 10,000 populations (lowest in Europe) and an exodus of our GP graduates. 
 
 GPs coordinate and facilitate high-quality repeat prescribing for patients. GPs issue a ‘repeat-
script’ every three to six months, but this can be more frequent if there is a clinical need. Whilst 
the GP takes the responsibility and assumes the risk  for  prescribing,  often  GPs  are  not  the  
original  doctor  who  starts  a medication. If a drug is initiated in hospital, the GP would issue 
the prescription on  a  GMS  script  for  a  GMS-eligible  patient  the  cost  then  comes  from  the 
community budget. 
 
The  ICGP supports  evidence-based and  cost-effective treatments in the  Irish healthcare 
setting (including prescribing). The ICGP also supports initiatives from the Medicines 
Management Programme to support effective prescribing. Opportunity costs are evidence 
throughout the healthcare system, where we spend money on low value products (with limited 
benefit and excessive costs), which results in other areas of our public healthcare system being 
under-funded. 
 
The second section outlines the evidence for trends in prescribing. Evidence from large, 
population-based studies have shown that prescribing of 10 of more drugs (called ‘excessive 
polypharmacy’), in over-65s, has increased from 2% in 1997 to 22% in 2012.Whilst prescribing 
has increased, the odds of potentially inappropriate prescribing in 2012 (versus 1997) 
having controlled for age and level of polypharmacy was 60% less. GPs and hospitals are 
prescribing more medications for an ageing and more multimorbid population, but are 
doing a better job at prescribing. 
 
The submission also looks at research from Irish cohort studies, including TILDA. One report 
has shown that in an older population reporting polypharmacy, using a system of reference 
pricing based on groups of similar drugs could potentially save up to €152.4 million per year. 
The submission then addresses trends in the prescribing of certain drug classes, including 
benzodiazepines, anti-depressants, opioids and antibiotics.  
 
We can discuss the prescribing trends in more detail in the questions and answers session, 
but we might anti-depressant prescribing now. In 2016, the State spent €40.07 million on 
anti-depressant medications for GMS eligible patients and €4.29 million on the Drug Payment 
Scheme. In contrast, we spent ~€10 million on Counselling in Primary Care was only. All 
evidence suggests that GPs prescribe extremely appropriately in the context of a severe 
capacity shortage in General Practice and Primary Care. Prescribing rates of anti-depressants 
reflect a lack of psychological therapies and a lack of social therapies and resources in society 
(including fragmented communities, isolation and austerity). 
 
The third section discusses some opportunities and challenges in relation to audit and data 
monitoring. We outline how it is pivotal that GPs are provided with sufficient time and 
resources to enable shared discussion on medicines management. When savings are made, 
it is of paramount importance, that savings are directed in appropriately funding Irish 
general practice. 
 
We need to address the challenge of medicines reconciliation across healthcare interfaces 
and promote electronic discharges, to reduce error and improve quality. The role of clinical 
pharmacists in the general practice team (or in the nursing home setting) should be 
explored, but as part of a new GP contract. Monitoring and audit of prescribing, if done  
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correctly, has the potential to be an extremely powerful tool for GPs in their on-going efforts 
to deliver the very best care for their patients. Research and audit needs to be actively 
supported and promoted at the highest level. We need to be careful, when using this data or 
when comparing raw prescribing data from individuals and comparing it to national 
standards. We need to take account of confounders such as poverty and deprivation, or 
conditions such as multimorbidity and depression. Continuous medical education has seen a 
curtailment in funding, which needs to be reversed. 
 
Pharmaceutical advertising (in the national media) indirectly promoting certain products has 
been an unwelcome development in recent years. This should come under legislative control 
as GPs are encountering demand for drugs and services, which have dubious cost-benefit.  
 
Lastly, the submission finishes with some recommendations. GPs  need  time  to  deal  with  
complex  cases.  This  will  require  a  modern  GP contract which facilitates the management 
of chronic conditions and medication management. Before this, there is need for the urgent 
reversal of FEMPI, which has curtailed the ability of general practices to grow, at a time 
when GP services should expand. We also need to retain our brightest and best GPs who see 
other healthcare systems as a preferable career option. ICGP is becoming increasingly 
frustrated with the lack of government action on these key matters. 
 
We need to direct any savings in drug prescribing back into General Practice to reinforce a 
cycle, which is to the benefit of the patient and of the health system more widely. A 
medicines management programme, led by GPs, needs to be created as part of a new 
contract. 
 
This committee should endorse a recommendation to ban non-governmental healthcare 
advertising, especially the indirect promotion of drugs in the media. The  ICGP  is  willing  to  
continue  to  work  and  collaborate  with  the  HSE  and educational bodies to promote cost-
effective, evidence-based prescribing. Sometimes collaboration has not happened (e.g. such 
as through online requirements for issuing certain drugs or for phased prescribing), which has 
disenfranchised and increased frustration with GPs. 
 
Prescribing trends can only be identified through research and audit. Academic career 
structures for GPs have not been sufficiently facilitated by the HSE or the Department of 
Health.  Similarly research on our electronic health records, such as that through the Irish 
Primary Care Research Network, is underdeveloped in the Irish setting, which will require an 
expansion and State funding. This will deliver savings in the future. 
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Section 1: Context to Prescribing Trends 
 
1.1. Rising Prevalence of Chronic Diseases 
 
Ireland has a rising prevalence of chronic illnesses, explained partly due to an ageing    
population. Approximately 10% of the Irish population is over 65, which will increase to over 
25% by 20401. Examples of chronic conditions include chronic respiratory conditions (e.g.   
COPD and asthma), cardiovascular illnesses, mental health conditions, arthritis and 
dementia.  
 
Multimorbidity is a medical term defined as an individual having two or more chronic 
illnesses. 65% of those aged more than 65 years and almost 82% of those aged 85 years or 
more have two or more chronic conditions. Patients with multimorbidity include one third of 
consultations in general practice2. Chronic illnesses should be managed with community 
services, led by GPs. This is a key but yet unrealised policy objective of successive 
governments3. 

Patients often expect medication solutions to medical problems. However, often 
psychological or social or lifestyle options, including conservative management, is the most 
effective option. It is estimated that two out of every three consultations result in a 
prescription4. Prescribing for both acute conditions and repeat prescribing for chronic 
conditions informs the majority of our working day. 
 
 
Table 1: An example of a typical patient in General Practice 5 
70 year old female patient with five 
‘chronic diseases’: 
 
 
 COPD 
 Diabetes 
 Hypertension 
 Arthritis 
 Osteoporosis 
Drug burden 
 
 
 19 doses of 12 different medications 
 Taken at five times during the day 
 10 different possibilities for drug-drug or drug- 
disease interactions 
 
Also, 14 non-drug activities recommended 
 
ICGP submission to the Joint Committee on Health on Prescribing Pattern Monitoring 
© ICGP March 2018 6 
 
 
 
   1.2. Increased Prescribing/Dispensing of Medications in the Community 
The 2016 PCRS Annual Report outlines the large costs and dispensing data for all drugs, 
which come from the community PCRS budget (whether prescribed in the community or 
not)6. 
 €1,003.29 million was spent by the State on medications for GMS-eligible 
patients 
 High Tech medications, paid  from  the  community  budget, cost  €631.23  
million. Hospital drugs, from oncology, Hepatitis C and outpatient parenteral 
antimicrobial therapy amounted to €68.5million. 
 €153.67 million was spent on the Drug Payment Scheme (DPS) 
 €207.45 million was spent on the Long Term Illness (LTI) Scheme 
 
 
 
Figure 1: The Top 10 Most Commonly Prescribed Products reimbursed by the GMS 
 
 Prescribing 
(million) 
frequency Cost (euro) (million) 
1. Aspirin 2.1  2.8 
2. Atorvastatin 1.8  7.2 
3. Thyroid hormone 1.7  2.8 
4. Paracetamol 1.4  2.3 
5. Esomeprazole 1.2  8.7 
6. Bisoprolol 1.2  2.7 
7. Salbutamol 1.1  5.0 
8. Calcium (combinations) 1.1  5.8 
9. Lansoprazole 0.9  4.8 
10. Codeine analgesics 0.6  6.2 
 
 
Figure 2: The Top 10 Products by Ingredient Cost reimbursed by the GMS 
 
 Cost (euro) (million) Prescribing frequency 
(million) 
1. Clinical Nutritional Products 45.4 0.6 
2. Pregabalin 24.8 0.7 
3. Salmeterol inhalers 23.7 0.5 
4. Lidocaine 21.6 0.3 
5. Ostomy requisites 16.1 0.2 
6. Formoterol inhalers 13.1 0.3 
7. Tiotropium inhalers 13.0 0.3 
8. Rivaroxaban 10.8 0.2 
9. Urinary requisites 9.9 0.1 
10. Denosumab 9.8 0.04 
 
In comparison, in 1998, for 1.18 million eligible GMS patient, drugs fees were as follows 6: 
 GMS pharmacy claims £203.15 million 
 DPS £47.2 million 
 LTI £23.2 million 
 High Tech Drugs Scheme £2.1 million 
 Methadone £1.5 million 
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1.3. Context of Irish General Practice 
Macro-economic picture: Compared to the ~€2 billion drug spend, which comes from the  
community  budget, in  2016 we spent  €394.8 million  on GP  fees  (and €148.33 million on 
GP expenses). The total expenditure in Irish General Practice- including  private  fees-  comes  
to  <  4.5%  of  the  total  healthcare  budget.  This compares to > 7-11% in other countries7. 
 
Out-dated contract and under-funded: General Practitioners work off a 40-year-old contract.  
FEMPI  has  also  taken  38%  from  most  GP’s  GMS  income,  which  has curtailed the 
services able to be provided to patients. 
 
Capacity restraints: Ireland has 6.2 GPs per 10,000 population7. 20% of recent GP graduates 
have immigrated to countries which prioritise a GP-led system8. At a time when GP-led, 
community orientated healthcare should have happened, we have seen a massive retraction 
in GP funding, when pharmaceutical spending has massively increased. 
 
Primary  care:  Prompt  access  to  our  colleagues  in  primary  care  can  enable  the 
promotion of non-drug treatment options. As an example, if a patient does not have access to 
a physiotherapist or a psychologist (or counsellor) it removes non-drug options from a 
management plan and can promote prescribing. 
 
 
 
1.4. Repeat Prescribing in the Irish Healthcare System 
Typically GPs issue a ‘repeat-script’ every three-six months, but this can be more frequently if 
there is a clinical need. Coordinating and facilitating high-quality and safe repeat prescribing 
for patients is a professional responsibility of the GP. 
 
For GMS-eligible patients, when prescribed a medication in a hospital setting, the medication 
needs to be transcribed by the GP onto a GMS prescription, after reconciling and confirming 
the script is accurate. Therefore, whilst the GP has ultimate responsibility to prescribe the 
medication, often GPs are not the original doctor who started the medication. So when a drug 
is initiated in hospital, then subsequently prescribed by the GP to make it GMS-eligible, the 
cost then comes from the community budget.  Example could include complex    pain    
medications,    which    may    come    from    rheumatology, orthopedics, palliative care pain 
clinics etc.; or benzodiazepines and anti- depressants, which may be started in psychiatry 
clinics. 
 
The ICGP has a comprehensive guidance document to advice our Members on the best 
practice principles when issuing repeat scripts. Issues with GPs consider include drug-disease 
interactions, drug-drug interactions and drug monitoring. 
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1.5. Cost-Effective Prescribing 
ICGP supports evidence-based, cost-effective prescribing. A key principle in the discipline of 
pharmaco-economics includes the concept of opportunity cost. This is evident throughout the 
healthcare system where we spend money on low  value  products  (with  limited  benefit  and  
excessive costs), which results in other areas of our public healthcare system being under-
funded. 
 
The ICGP supports the input Medicine Management Programme of the HSE in the preferred 
prescribing information and their Tips and Tools guidelines. This information can help GPs 
deliver more informed prescribing us with relevant pharmaco-economic information. 
 
 
Section 2: Evidence on Prescribing Trends 
 
Raw dispensing data is important, but does not tell us about the underlying complexities of 
prescribing. It does not factor important variables such as degree of morbidity, age of the 
patient, deprivation etc. It also does not tell us whether a prescription is appropriate or not. 
We are lucky in Ireland, despite difficulties accessing data for researchers, that analysis of 
PCRS data and specific research studies have helped shed light on prescribing trends. 
 
 
The HRB Centre for Primary Care Research, since 2008, has looked at trends of prescribing. 
One paper by Frank Moriarty et al. (published in BMJ Open in 2015) looked at trends in 
prescribing - specifically 'potentially  inappropriate prescribing'- from 1998 to 20129. 
 
Overall  prescribing  has  increased  year  on  year  from  1997  to  2012, explained by an 
older population with more chronic disease: 
 
 In over-65s, prescribing of 5 of more drugs (called ‘polypharmacy’) in over 65s 
increased from 18% in 1997 to 60% in 2012. 
 In over-65s, prescribing of 10 of more drugs (called ‘excessive 
polypharmacy’) increased from 2 to 22%. 
 
The odds of ‘potentially inappropriate prescribing’ in 2012 (versus 1997), having controlled 
for age and level of polypharmacy, was 60% less. This   would   suggest   that   GPs   and   
hospitals   are   prescribing   more medications for an ageing and more multimorbid 
population, but are doing a better job at prescribing. 
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Figure 3: Percentage of Eligible Population by Number of Regular Medicines for the 
Years 1997-2012
9 
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A cohort study, the Irish Longitudinal Study on Ageing (TILDA), has delivered important 
information on prescribing trends in older adults in Ireland1: 
 Medications used to treat cardiovascular conditions (mainly high blood 
pressure and heart disease) are the most common medications contributing 
to polypharmacy. 
 Currently one in five medicines used by those reporting polypharmacy is a 
generic, 15% being a branded generic and 6% a pure generic. The report sound 
that increasing the use of generic medicines could potentially save up to €29.5 
million per year. 
 In the older population reporting polypharmacy, using a system of reference 
pricing based on groups of similar drugs could potentially save up to €152.4 
million per year. 
 
 
Another cohort study11, developed by Dr Emma Wallace et al. in the HRB Centre for 
Primary Care Research, has shown that older community-dwelling people, prescribed ≥2 
potentially inappropriate medications are more likely to report adverse drug events, 
poorer health related quality of life and attend the emergency department over a two-
year follow-up. 
 
 
2.1 Anti-Depressants: 
The majority of mental health conditions are managed within General Practice. GPs and 
psychiatrists manage depression and anxiety in accordance with evidence-based guidelines. 
All mental health conditions require a bio-psych-social approach to their management; 
whilst psychosocial options are arguably the most important component of managing any 
condition, drug options have a definite evidence base for certain conditions.  
 
It is worth considering the overall context and costs. In 2016, the State spent €40.07 
million on anti-depressant medications for GMS eligible patients and €4.29 million on the 
Drug Payment Scheme. In contrast, the spend on counselling in primary care was only ~€10 
million6. Prescribing rates of anti-depressants reflect a lack of psychological therapies and a 
lack of social therapies and resources in society (including fragmented communities, 
isolation and austerity). Limited public (free) access to psychosocial services 
disproportionately affects those without ability to pay and forces an increased use of 
medication options. 
 
There is no evidence GPs are over-prescribing anti-depressants, but the failure to resource 
psychological  services  may  increase  the  likelihood  of  prescribing medications, as mental 
health conditions can worsen. This is not an issue for GPs to manage in isolation. Enhanced 
HSE psychological supports would greatly improve options for GPs in the area of mental 
health management. Anecdotal feedback on the experiences of GPs with the HSE 
community counselling service is that it is difficult to access, waiting times are too long and 
there are a lot of exclusion criteria. 
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2.2 Benzodiazepines and Z-Drugs: 
The most recent data suggests that benzodiazepine prescribing has stabilised but remains 
higher than desired. On the other hand prescribing of “z” hypnotics has been increasing. 
Chronic benzodiazepine prescribing (> 8 weeks) has been reducing over the past 15 years. 
The continuation of chronic benzodiazepine prescribing is largely related to legacy 
prescribing, in which patients are on these medications for over ten years and have 
developed a tolerance to these medications. 

There needs to be a consistent approach to this issue across the healthcare system 
as this is not simply an issue for primary care- it is recognised that prescribing of these 
medications is initiated in hospitals and psychiatry units also. 

The ICGP was closely involved in the development of the new benzodiazepine receptor 
agonist guidelines (BZRA), issued recently by the HSE Medicine Management Unit. All 
GPs will be issued with summary of these guidelines, which offers doctors tips and tools 
for reducing long term BZRA use. There is greater awareness of the issues related to 
prescribing BZRA medications for long- term use. Through education and greater 
awareness particularly during GP training, we would anticipate that appropriate 
prescribing in keeping with the guidelines can be achieved. 
 
 
2.3 Opiates: 
ICGP is aware of the opiate crisis in the US and all efforts should be made to avoid a 
similar experience in Ireland. But like the medications addressed above, GPs are at the 
front line and it is difficult when a patient is sitting in front of the GP, disabled with 
intractable pain, possibly waiting years for an orthopedic or a pain clinic appointment. 
 
Prescribing guidelines for the appropriate use of opiates in pain are in discussion. The ICGP 
is represented in the Faculty of Pain Management of the College of Anesthetists. 
Education for all GPs and GP Trainees is being enhanced on the area of pain 
management. 
 
Evidence does not support the use of opiates for non-cancer pain. We must be aware 
of the strong influence of pharmaceutical marketing, which promote an increasing array of 
opioid medications offering solutions for chronic pain. Increasing awareness  of  at  risk  
patient  groups  and  encouraging  closer  collaboration  with specialist pain services so that 
at risk patient can be identified prior to prescribing opiates is desirable. 
 
 
2.4 Antibiotic stewardship: 
The MMU has produced prescribing data, information and guidelines for appropriate 
antibiotic prescribing. The ICGP supports the HSE initiatives such as  the patient 
information campaign “Under the Weather” which reinforces the message that most 
minor illnesses are viral and can be managed safely without the use of antibiotics. 
 
Antibiotic stewardship involves ensuring a doctor is prescribing the right antibiotic for the 
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right patients, with the right dose, route and duration, causing the least harm to the patient. 
A core focus of antibiotic stewardship involves limiting the development of antibiotic 
resistance. Irish data has shown that nursing home prescribing. Barriers to effective 
antibiotic stewardship have been outlined as12: 
 Lack of true community resistance data 
 Lack of accurate antibiotic data 
 Lack of access to diagnostics laboratory and near patient e.g. CRP 
 Lack of access to experts in microbiology/ care of the elderly etc. for complex 
cases 
 Lack of leadership and governance 
 Lack of time 
 
 
 
Section 3: Challenges for Audit and Prescription Monitoring 
 
 
3.1 Challenges Facing Irish General Practice, Particularly Time 
The introduction of FEMPI, the extension of the GMS to cover under 6 and over 70 years 
along with a manpower crisis contribute to GPs having less time to give to individual 
patients with complex problems. It takes time to prescribe effectively, efficiently and safely, 
to follow guidelines and to reconcile medications. 

It cannot be over-emphasised and FEMPI and a lack of support for general practice has 
reduced the time for GPs to share decisions with patients. Also, there is no specific 
medicines management programme in our current contract. 
 
Medicines management involves a quantum of time and workload, which has not been 
reflected by the HSE or DoH. An example would be the online requirements for GPs to 
permit phased prescribing or to prescribe a certain drug which was not initiated in General 
Practice (e.g. lidocaine patches). This workload needs to be resourced. This lack of 
collaboration has only heightened the frustration amongst GPs. 
 
 
3.2 Where Should Savings be Directed? 
Any savings in the drug budget, generated by GPs, need to be fed back in to General 
Practice to reinforce a cycle, which is to the benefit of the patient and of the health 
system more widely. 
 
 
3.3 Medicines Reconciliation between Healthcare Interfaces 
One of the biggest risks to patient safety is when patients cross boundaries of care. This is 
especially true on discharge from secondary care to General Practice. Redmond et  al.  
demonstrated that  80%  of GPs  and pharmacists  recall a prescribing error following a 
transition of care, in the preceding six months 13. Audits have shown >30% of paper hospital 
discharges do not have accurate information on prescriptions. 
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The ICGP Quality in Practice programme and GP-IT group has supported initiatives to 
improve safety and reduce risk at these transitions. E-referrals to hospitals have facilitated 
accurate information arriving at hospitals. However, E-discharges have largely been 
neglected. Discharge letters from secondary care settings- such as outpatients, Emergency 
Departments and post admission need to be standardized. It is common for a GP and 
patient to be unsure of what is written on a prescription, what medications were started, 
what medications were stopped and to be unable to read the name or bleep number of 
the prescriber in the secondary care setting. This is an unacceptable breech in patient 
safety. Standardised discharges, ideally through e-Discharges, would improve safety, 
efficiency and deliver clarity and accountability. Ideally an electronic pro forma to include 
a medication-list, plus comments on any changes made to the admission medications. 
 
 
 
3.4 Role of Pharmacists in Repeat Prescribing and Data Monitoring 
The community pharmacist is an essential and extremely valued member of the primary 
care team. The current role of the community pharmacist, with the GP as the prescriber, 
promotes safety for patients through a prescriber-dispenser split. 
 
Rationalisation of medications and de-prescribing is a major challenge. The role of 
practice-based pharmacists (not community pharmacists) has an emerging evidence base-  
especially  looking  at  at-risk  groups  such  as  nursing  home  residents  and patients with 
excessive polypharmacy. HSE pilots are underway. Pending a review of this evidence, ICGP 
would like to collaborate on recommendations on how pharmacists could be integrated into 
the primary care teams, or even practice based teams, but needs to be considered in terms 
of overall GP contract. 
 
 
 
3.5 Use of Data to Monitor Prescribing and for Self-Audit 
Monitoring and audit of prescribing, if done correctly, has the potential to be an 
extremely powerful tool for GPs in their on-going efforts to deliver the very best care for 
their patients. 
 
When comparing individual performance to national norms, we need to take account of 
confounders such as poverty and deprivation. Prescribing patterns are likely to be affected 
by consultation times most especially in the areas of multimorbidity and depression. The 
use of data to develop a centrally-controlled, regimented prescribing pattern without 
reference to individual clinical judgement is a risk. For an individual patient, the cheapest 
prescribing may not be developing the best result with possible relapse and a need for 
further hospital care. The risk is  that  the  state  will  only  see  the  price  and  not  the  
clinical  outcome. 
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Research: 
The ICGP supports research on prescribing trends, through collaboration with university 
departments, funding   higher   degrees for GPs interested in research and development of 
research networks. One research network is called the Irish Primary Care Research 
Network. It is a powerful tool, which has the potential to support rapid analysis of 
prescribing trends (for research purposes only, iPCRN and research). 
 
Research costs money and funding, e.g. for the IPCRN, needs to be State funded. 
Looking at datasets in abroad (e.g. CPRD in the UK) highlights what a lost  opportunity  we  
have  in  Ireland,  due  to  the  lack  of  funding  of  this research. 
 
 
Audit: 
Audit involves comparing current clinical practice against best practice, with a view to 
improving quality. ICGP supports GPs, as part of their annual professional competence 
cycle, to perform an audit on prescribing data. Use of the IPCRN facilitates this. 
 
The ICGP welcomes the prescribing feedback they receive from the Primary Care 
Reimbursement Service of the HSE. This allows individual GPs to reflect on their 
prescribing of benzodiazepines and to see where there prescribing levels are in 
comparison to their peers. The limitation of this process is that it only  captures  GMS  
prescribing  and  the  data  on  private  scripts  is  not captured. 
 
 
3.6 Pharmaceutical Advertising 
The advertising for medical services from commercial companies in the national 
media has been an unwelcome development in recent years. This follows an American 
model where such advertising involves very extensive advertising of drugs with an 
exhortation to discuss them with the doctor. Unless this practice comes under 
legislative control it is likely that patient pressure driven by marketing will result in GPs 
encountering demand for drugs and services with dubious cost benefit. 
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Conclusion 
Medicine is unrecognisable now compared to twenty years ago. More patients are living 
with chronic conditions. More patients are prescribed multiple, expensive medications. It is 
GPs who generate and/ or coordinate the prescribing of these medications, but funding for 
Irish General Practice has been cut and is behind all other developed countries. When our 
health  services  should  have  moved  towards  a  GP-led,  community  orientated  system, 
funding for General Practice has retracted and GPs have less time. 
 
 
ICGP wishes to make the following recommendations to the Joint Committee on Health: 
 
 GPs need time to deal with complex cases.  This will require a modern GP 
contract which facilitates the management of chronic conditions and medication 
management. Before this, there is need for the urgent reversal of FEMPI, which has 
curtailed the ability of General Practices to grow, at a time when GP services should 
expand. We also need to retain our brightest and best GPs who see other healthcare 
systems as a preferable career option. ICGP is becoming increasingly frustrated with 
the lack of government action on these key matters. 
 We need to direct any savings in drug prescribing back into General Practice to 
reinforce a cycle, which is to the benefit of the patient and of the health system 
more widely. 
 A medicines management programme, led by GPs, needs to be created as part of a 
new contract. 
 This committee should endorse a recommendation to ban non-governmental 
healthcare advertising, especially the indirect promotion of drugs in the media. 
 The  ICGP  is  willing  to  continue  to  work  and  collaborate  with  the  HSE  and 
educational bodies to promote cost-effective, evidence-based prescribing. Sometimes 
collaboration has not happened (e.g. such as through online requirements for issuing 
certain drugs or for phased prescribing), which has disenfranchised and increased 
frustration with GPs. 
 Prescribing trends can only be identified through research and audit. Academic 
career structures for GPs have not been sufficiently facilitated by the HSE or the 
Department of Health.  Similarly research on our electronic health records- such as 
that through the Irish Primary Care Research Network- is underdeveloped in the 
Irish setting, which will require an expansion and State funding. This will deliver 
savings in the future. 
ICGP submission to the Joint Committee on Health on Prescribing Pattern Monitoring 
© ICGP March 2018 16 
 
 
 
 
References: 
 
 
1.   IMO. Solving the Chronic Disease Problem through General Practice. Dublin: Irish 
Medical Organisation; 2016. Available Online: https://www.imo.ie/news-
media/events/2016/solving-the-chronic- disea/Solving-the-Chronic-Disease-
Problem-Booklet.pdf [Accessed 20th March 
2018] 
2.   Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of 
multimorbidity and implications for health care, research, and medical 
education: a cross-sectional study. Lancet. 2012 Jul 7;380(9836):37-43. doi: 
10.1016/S0140-6736(12)60240-2. Epub 2012 May 10. 
3.   Houses of the Oireachtas. Committee on the Future of Healthcare. Slaintecare 
Report. May 2017. Available Online: 
https://www.oireachtas.ie/parliament/media/committees/futureofhealthcar e/ 
Oireachtas-Committee-on-the-Future-of-Healthcare-Slaintecare-Report- 
300517.pdf [Accessed 20th March 2018] 
4.   Duerden M, Millson D, Avery A, Smart S. The quality of GP prescribing. London: 
The King’s Fund; 2011. Available Online: 
https://www.kingsfund.org.uk/sites/default/files/field/field_document/quality 
-gp-prescribing-gp-inquiry-research-paper-mar11.pdf [Accessed 20th March 
2018] 
5.   Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines 
and quality of care for older patients with multiple comorbid diseases: 
implications for pay for performance. JAMA. 2005 Aug 10;294(6):716-24. 
6.   HSE. Primary Care Reimbursement Service: Statistical Analysis of Claims and 
Payments 2016. Dublin: HSE; 2016. Available Online: 
https://www.hse.ie/eng/staff/pcrs/pcrs-publications/pcrs-annual-report- 
20161.pdf [Accessed 20th March 2018] 
7.   O’Dowd, T.; Trinity College Dublin. A future together – building a better GP and 
Primary Care Service. Dublin: HSE; 2017. Available Online: 
http://hse.ie/eng/services/list/2/PrimaryCare/gp-and-primary-care/a-future- 
together.pdf [Accessed 20th March 2018] 
8.   Pericin I, Mansfield G, Larkin J and Collins C. Future career intentions of recent 
GP graduates in Ireland: a trend analysis study. BJGP Open 20 February 2018; 
bjgpopen18X101409. DOI:  https://doi.org/10.3399/bjgpopen18X101409. 
9.   Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of 
polypharmacy and potentially inappropriate prescribing in primary care over 15 
years in Ireland: a repeated cross-sectional study. BMJ Open 2015 Sep 
18;5(9):e008656-2015-008656. 
10. Richardson K, Moore P, Peklar J, Galvin R, Bennett K, Kenny RA. (TILDA) 
Polypharmacy in adults over 50 in Ireland: Opportunities for cost saving and 
improved healthcare. 2012; Available Online: 
ICGP submission to the Joint Committee on Health on Prescribing Pattern Monitoring 
© ICGP March 2018 17 
 
 
 
 
https://tilda.tcd.ie/publications/reports/pdf/Report_Polypharmacy.pdf. 
[Accessed 20th March 2018] 
11. Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of Potentially 
Inappropriate Prescribing on Adverse Drug Events, Health Related Quality of Life 
and Emergency Hospital Attendance in Older People Attending General Practice: 
A Prospective Cohort Study. J Gerontol A Biol Sci Med Sci 2017 Feb;72(2):271- 
277. 
12. O'Connor N. Antibiotics in the community. 2016; Available Online: 
https://www.hse.ie/eng/services/publications/clinical-strategy-and- 
programmes/antibiotics-in-the-community-dr-nuala-o-connor1.pdf. [Accessed 
20th March 2018] 
13. Redmond P, Carroll H, Grimes T, Galvin R, McDonnell R, Boland F, et al. GPs' and 
community pharmacists' opinions on medication management at transitions of 
care in Ireland. Fam Pract 2016 Apr;33(2):172-178. 
